065 - Proteomic technology for preclinical diagnosis of autoimmune diseases
Autor(s): N. Bizzaro
Issue: RIMeL - IJLaM, Vol. 4, N. 3-S1, 2008 (MAF Servizi srl ed.)
Page(s): 65-67
Both retrospective and prospective studies have shown clearly that disease specific autoantibodies can be detected months to several years before clinical manifestation of the corresponding disease. Multiple autoantibody determination systems can prospectively be used for preventive screening of open populations or at-risk groups, with significant practical implications (earlier diagnosis and treatment). Proteomic-based technology meets these requirements and could enable detection of autoantibody signatures able to drive the development and selection of antigen- specific therapies for autoimmune diseases. However, practical and ethical aspects should be carefully considered before these methods are used in clinical practice